These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 10535273)

  • 1. Hepatitis C and iron.
    Olynyk JK
    Keio J Med; 1999 Sep; 48(3):124-31. PubMed ID: 10535273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatic iron overload in patients with chronic viral hepatitis: role of HFE gene mutations.
    Piperno A; Vergani A; Malosio I; Parma L; Fossati L; Ricci A; Bovo G; Boari G; Mancia G
    Hepatology; 1998 Oct; 28(4):1105-9. PubMed ID: 9755249
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liver iron accumulation in patients with chronic active hepatitis C: prevalence and role of hemochromatosis gene mutations and relationship with hepatic histological lesions.
    Hézode C; Cazeneuve C; Coué O; Roudot-Thoraval F; Lonjon I; Bastie A; Duvoux C; Pawlotsky JM; Zafrani ES; Amselem S; Dhumeaux D
    J Hepatol; 1999 Dec; 31(6):979-84. PubMed ID: 10604569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis C, iron, and hemochromatosis gene mutations. A meaningful relationship or simple cohabitation?
    Snover DC
    Am J Clin Pathol; 2000 Apr; 113(4):475-8. PubMed ID: 10761447
    [No Abstract]   [Full Text] [Related]  

  • 5. [Iron as comorbid factor in chronic hepatitis C].
    Erhardt A; Hauck K; Häussinger D
    Med Klin (Munich); 2003 Dec; 98(12):685-91. PubMed ID: 14685669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Semiquantitative and qualitative assessment of hepatic iron in patients with chronic viral hepatitis: relation with grading, staging and haemochromatosis mutations.
    Vergani A; Bovo G; Trombini P; Caronni N; Arosio C; Malosio I; Fossati L; Roffi L; Piperno A
    Ital J Gastroenterol Hepatol; 1999; 31(5):395-400. PubMed ID: 10470600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Iron deposition and progression of disease in chronic hepatitis C. Role of interface hepatitis, portal inflammation, and HFE missense mutations.
    Pirisi M; Scott CA; Avellini C; Toniutto P; Fabris C; Soardo G; Beltrami CA; Bartoli E
    Am J Clin Pathol; 2000 Apr; 113(4):546-54. PubMed ID: 10761457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heterozygosity for hereditary hemochromatosis is associated with more fibrosis in chronic hepatitis C.
    Smith BC; Gorve J; Guzail MA; Day CP; Daly AK; Burt AD; Bassendine MF
    Hepatology; 1998 Jun; 27(6):1695-9. PubMed ID: 9620344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The H63D genetic variant of the HFE gene is independently associated with the virological response to interferon and ribavirin therapy in chronic hepatitis C.
    Carneiro MV; Souza FF; Teixeira AC; Figueiredo JF; Villanova MG; Secaf M; Passos AD; Ramalho LN; Carneiro FP; Zucoloto S; Candolo Martinelli AL
    Eur J Gastroenterol Hepatol; 2010 Oct; 22(10):1204-10. PubMed ID: 20555268
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of iron overload and HFE gene mutations in the era of pegylated interferon and ribavirin treatment of chronic hepatitis C.
    Sikorska K; Stalke P; Izycka-Swieszewska E; Romanowski T; Bielawski KP
    Med Sci Monit; 2010 Mar; 16(3):CR137-143. PubMed ID: 20190684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Body iron stores and iron restoration rate in Japanese patients with chronic hepatitis C as measured during therapeutic iron removal revealed neither increased body iron stores nor effects of C282Y and H63D mutations on iron indices.
    Shiono Y; Hayashi H; Wakusawa S; Sanae F; Takikawa T; Yano M; Yoshioka K; Saito H
    Nagoya J Med Sci; 2001 May; 64(1-2):51-7. PubMed ID: 11486601
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HFE gene mutations prevent sustained virological response to interferon plus ribavirin in chronic hepatitis C patients with serum markers of iron overload.
    Coelho-Borges S; Cheinquer H; Cheinquer N; Krug L; Ashton-Prolla P
    Am J Gastroenterol; 2002 Jun; 97(6):1570-2. PubMed ID: 12094895
    [No Abstract]   [Full Text] [Related]  

  • 13. Iron and liver diseases.
    Fargion S; Mattioli M; Fracanzani AL; Fiorelli G
    Can J Gastroenterol; 2000 Nov; 14 Suppl D():89D-92D. PubMed ID: 11110619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relative contribution of iron genes, dysmetabolism and hepatitis C virus (HCV) in the pathogenesis of altered iron regulation in HCV chronic hepatitis.
    Valenti L; Pulixi EA; Arosio P; Cremonesi L; Biasiotto G; Dongiovanni P; Maggioni M; Fargion S; Fracanzani AL
    Haematologica; 2007 Aug; 92(8):1037-42. PubMed ID: 17640859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatitis C, iron status, and disease severity: relationship with HFE mutations.
    Tung BY; Emond MJ; Bronner MP; Raaka SD; Cotler SJ; Kowdley KV
    Gastroenterology; 2003 Feb; 124(2):318-26. PubMed ID: 12557137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Roles of iron and HFE mutations on severity and response to therapy during retreatment of advanced chronic hepatitis C.
    Bonkovsky HL; Naishadham D; Lambrecht RW; Chung RT; Hoefs JC; Nash SR; Rogers TE; Banner BF; Sterling RK; Donovan JA; Fontana RJ; Di Bisceglie AM; Ghany MG; Morishima C;
    Gastroenterology; 2006 Nov; 131(5):1440-51. PubMed ID: 17101320
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Iron and HFE or TfR1 mutations as comorbid factors for development and progression of chronic hepatitis C.
    Bonkovsky HL; Troy N; McNeal K; Banner BF; Sharma A; Obando J; Mehta S; Koff RS; Liu Q; Hsieh CC
    J Hepatol; 2002 Dec; 37(6):848-54. PubMed ID: 12445428
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Iron genes, dysmetabolism and fibrosis in chronic hepatitis C.
    Valenti L; Dongiovanni P; Fargion S; Fracanzani AL
    J Hepatol; 2008 Mar; 48(3):513-4; author reply 514-5. PubMed ID: 18194822
    [No Abstract]   [Full Text] [Related]  

  • 19. Raised serum ferritin predicts non-response to interferon and ribavirin treatment in patients with chronic hepatitis C infection.
    Distante S; Bjøro K; Hellum KB; Myrvang B; Berg JP; Skaug K; Raknerud N; Bell H
    Liver; 2002 Jun; 22(3):269-75. PubMed ID: 12100578
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatic iron overload and risk of hepatocellular carcinoma in cirrhosis.
    Nahon P; Ganne-Carrié N; Trinchet JC; Beaugrand M
    Gastroenterol Clin Biol; 2010 Jan; 34(1):1-7. PubMed ID: 19762191
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.